DSIP
Delta sleep-inducing peptide — a name bigger than the evidence
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
Summary
Delta sleep-inducing peptide, a nine-amino-acid peptide isolated in the 1970s from the cerebral venous blood of sleeping rabbits. The name comes from the initial observation of increased delta activity. Subsequent human research is scarce and inconsistent with the promise of the name.
Quick reference
- Route
- Subcutaneous is the most described format. Old human trials used short IV infusion.
- Schedule
- Single dose at night, 1–3 h before intended sleep, in short cycles.
- Measure
- Vial concentration and U-100 syringe units for small volumes.
- Status
- Not approved. In FDA Category 2, with PCAC review in July 2026.
Protocol and dosing schedule
| Pattern | Typical range | Route | Notes |
|---|---|---|---|
| Older human trials | 25 nmol/kg | IV | Short 4-7 night courses; published 1981-1987 in middle-aged chronic insomniacs. |
| Lower research planning | 100-200 mcg | SubQ | Most common community range; described in research write-ups, not clinical trials. |
| Higher research planning | 200-300 mcg | SubQ | Used in some research write-ups; tolerability and side-effect data are sparse. |
Cycle Guidelines
| Approach | Duration | Review point | Typical context |
|---|---|---|---|
| Short course | 5-7 nights | End of week 1 | Mirrors published human trial windows. |
| Standard cycle | 4 weeks | Week 4 | General research planning context. |
| Extended cycle | 6–8 weeks | Week 6 | Less common; long-term safety data is limited. |
DSIP Reconstitution Guide
| Vial | BAC water added | Concentration | 100 mcg draw | 200 mcg draw | 300 mcg draw |
|---|---|---|---|---|---|
| 10 mg | 2.0 mL | 5.0 mg/mL (5,000 mcg/mL) | 0.02 mL = 2 units | 0.04 mL = 4 units | 0.06 mL = 6 units |
DSIP vs Melatonin vs Epitalon vs Benzodiazepines
| Compound | What it is | Mechanism (in plain English) | Regulatory status (US) |
|---|---|---|---|
| DSIP | Nonapeptide | Modulates sleep architecture; not a sedative. | Not FDA-approved · Category 2 (2023) · PCAC July 2026 |
| Melatonin | Hormone supplement | Shifts sleep timing via the circadian system. | OTC supplement |
| Epitalon | Tetrapeptide | Studied for circadian/longevity markers; sleep effects anecdotal. | Not FDA-approved · research-use |
| Benzodiazepines | Prescription drugs | GABA-A agonists; sedate but degrade sleep architecture. | FDA-approved prescription drugs |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.